The company's lead product candidate, INO-4800, a DNA-based COVID-19 vaccine, remains a focal point of its pipeline, particularly for markets seeking alternatives to traditional mRNA vaccines.

What Else: Inovio's lead candidate, INO-4800, a DNA-based COVID-19 vaccine, remains a key focus among vaccine-makers, particularly as alternative vaccine technologies gain traction. The company is ...

As it stands only three vaccines – one from the Beijing ... study due to complete in the next couple of weeks. Inovio’s DNA-based INO-4800 candidate is slightly further back in testing ...